GT BIOPHARMA, INC.

9350 Wilshire Blvd.

Suite 203

Beverly Hills, CA 90212

April 23, 2021

Via EDGAR Submission

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention:   Chris Edwards

Re: 

GT Biopharma, Inc.

Registration Statement on Form S-1

CIK No. 0000109657

SEC Registration No. 333-255429

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-255429) (the “Registration Statement”) of GT Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 27, 2021, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Baker & McKenzie LLP by calling Roger Bivans at (214) 978-3095.

Thank you for your assistance with this matter.

Very truly yours,

/s/ Michael Handelman

Michael Handelman

Chief Financial Officer

Click here to enter Sender1 Email Address.